pharmaceuticals AM market analysis — 2026-08-11

Pharmaceutical manufacturing strategy is being reshaped by US tariff and most-favoured-nation policy discussions, which are pushing drugmakers toward domestic and regional production. Industry analysis from Logistics Viewpoints cautions this is more likely to produce regional, redundant supply networks than a wholesale exit from global manufacturing, meaning international production will stay embedded in the sector even as reshoring incentives grow.

A separate and unrelated pressure point concerns regulatory evidence quality. Research from Oregon State University finds some recent FDA approvals rest on narrower clinical trial evidence and disclose less information publicly than in the past, a trend that could feed through to how prescribers, payers, and investors weigh confidence in new-drug launches.

Contract manufacturing is gaining strategic weight as complex biologics, including antibody-drug conjugates, require specialised handling and conjugation capacity. Combined with tariff-driven interest in North American supply-chain integration across the United States, Mexico, and Canada, this points to CDMOs with advanced capabilities and regional footprints becoming more central to sourcing decisions.

Taken together, the sector is navigating two distinct threads: a slow, policy-driven reorganisation of where drugs are made, and a quieter shift in how much evidence underpins new approvals. Neither has resolved, and the read-through for positioning remains mixed rather than directional.